SCHEMBL12045145

SCHEMBL12045145

CCc1ccc(C2(C)COC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.56
CACNA1H O95180 7/20 0.37
TP53 P04637 2/20 0.36
TAAR1 Q96RJ0 1/20 0.35
CACNA1G O43497 1/20 0.35
CACNA1I Q9P0X4 1/20 0.35
CYP2A6 P11509 1/20 0.34
LPL P06858 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
FKBP1A P62942 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18571103 0.80 TP53 (0.40) KCNH2TP53TAAR1CYP2A6LPL
SCHEMBL19194397 0.80 CCR9 (0.40) KCNH2TP53TAAR1CYP2A6LPL
SCHEMBL19360668 0.77 OPRM1 (0.37) KCNH2TP53TAAR1CYP2A6LPL
SCHEMBL22918343 0.76 PRKAB2 (0.36) KCNH2TP53TAAR1CYP2A6LPL
SCHEMBL31558516 0.76 KCNH2 (0.65) KCNH2CACNA1HCACNA1GCACNA1I
SCHEMBL17316710 0.76 KCNH2 (0.49) KCNH2CACNA1HCACNA1GCACNA1IALDH1A1
SCHEMBL13351707 0.76 KCNH2 (0.47) KCNH2CACNA1H
SCHEMBL22593719 0.75 EPHX1 (0.38) KCNH2TP53TAAR1CYP2A6LPL
SCHEMBL16593763 0.75 RAB9A (0.37) TP53TAAR1CYP2A6LPLLIPG
SCHEMBL31558427 0.74 KCNH2 (0.55) KCNH2CACNA1HCACNA1GCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160194316-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2016-07-07 US disclosed
US-20160031907-A1 Substituted Benzene Compounds Epizyme, Inc. 2016-02-04 US disclosed
US-20160024081-A1 Substituted 6,5-Fused Bicyclic Heteroaryl Compounds Epizyme, Inc. 2016-01-28 US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK KCNH2 2252/4885CACNA1H 4391/4885TP53 2968/4885
US-20160024081-A1 Substituted 6,5-Fused Bicyclic Heteroaryl Compounds CYP3A5, PAICS, CYP4B1 KCNH2 2979/4885CACNA1H 4648/4885TP53 32/4885
US-20160031907-A1 Substituted Benzene Compounds CYP1B1, CYP4B1, CYP2B6 KCNH2 1446/4885CACNA1H 3612/4885TP53 11/4885
US-20160194316-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL KCNH2 1223/4885CACNA1H 3545/4885TP53 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.